|Solubility:||DMSO 30 mg/mL|
|Long-term Storage:||at -20°C|
|HPLC:||Shows Min >98% purity|
|H-NMR:||Consistent with structure|
|Description:||GNF-7 is the first type II inhibitors capable of inhibiting T315I to be described and will serve as a valuable lead to design next generation Bcr-Abl kinase inhibitors.|
|Stability and Solubility Advice:|| Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month.